Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-κB/NLRP3 inflammasomes pathway

J Drug Target. 2020 Jan;28(1):70-79. doi: 10.1080/1061186X.2019.1616296. Epub 2019 Jul 16.

Abstract

There is increasing evidence that atherosclerosis is the significant risk factor for cardiovascular diseases, which are the leading causes of morbidity and mortality worldwide. Artemisinin is a natural endoperoxides quiterpene lactone compound in Artemisia annua L with vasculoprotective effects. The primary aim of this study was to investigate whether artemisinin could be conferred an anti-atherosclerotic effect in high-fat diet (HFD)-fed ApoE-/- mice and explore the possible mechanism. We found that treatment with artemisinin (50 and 100 mg/kg) effectively ameliorated atherosclerotic lesions, such as foam cell formation, hyperplasia and fibrosis in the aortic intima. Atherosclerotic mice treated with artemisinin showed reduced inflammation by up-regulating adenosine 5'-monophosphate (AMP) activated protein kinase (AMPK) activation and by down-regulating nuclear factor-κB (NF-κB) phosphorylation and nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome expression in the aortas. In addition, artemisinin was found to promote AMPK activity in macrophages and its anti-inflammatory effect was neutralised by AMPK silence using specific siRNA. In conclusion, we demonstrate that artemisinin may protect the aortas from atherosclerotic lesions by suppression of inflammatory reaction via AMPK/NF-κB/NLRP3 inflammasomes signalling in macrophages.

Keywords: AMPK/NF-κB/NLRP3 inflammasomes signalling; Atherosclerosis; artemisinin; inflammation; macrophage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / drug effects
  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Artemisinins / administration & dosage
  • Artemisinins / pharmacology*
  • Atherosclerosis / pathology
  • Cell Culture Techniques
  • Diet, High-Fat
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Inflammasomes / drug effects*
  • Inflammasomes / metabolism
  • Inflammation / drug therapy
  • Inflammation / pathology
  • Inflammation Mediators / metabolism*
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Male
  • Mice
  • NF-kappa B / drug effects
  • NF-kappa B / metabolism
  • NLR Family, Pyrin Domain-Containing 3 Protein / drug effects
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism

Substances

  • Artemisinins
  • Inflammasomes
  • Inflammation Mediators
  • NF-kappa B
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • artemisinin
  • AMP-Activated Protein Kinases